Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Catalyst Biosciences, Inc. CBIO
$0.23
+$0 (1.82%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
8751980.00000000
-
week52high
2.09
-
week52low
0.19
-
Revenue
794000
-
P/E TTM
-1
-
Beta
1.18581300
-
EPS
-0.27000000
-
Last Dividend
1.67000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Market Perform | Outperform | 15 ноя 2021 г. |
| Raymond James | Outperform | Outperform | 06 авг 2021 г. |
| Raymond James | Outperform | Outperform | 29 апр 2021 г. |
| Piper Sandler | Overweight | 10 февр 2021 г. | |
| Raymond James | Outperform | Outperform | 04 февр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Blouse Grant E. | A | 9417 | 3250 | 09 авг 2022 г. |
| Miller Seline E. | A | 6500 | 3250 | 09 авг 2022 г. |
| USMAN NASSIM | A | 24541 | 3250 | 09 авг 2022 г. |
| Blouse Grant E. | A | 200000 | 200000 | 11 февр 2022 г. |
| Miller Seline E. | A | 107500 | 107500 | 11 февр 2022 г. |
| USMAN NASSIM | A | 21291 | 3250 | 09 февр 2022 г. |
| Miller Seline E. | A | 3250 | 3250 | 09 февр 2022 г. |
| Blouse Grant E. | A | 6167 | 3250 | 09 февр 2022 г. |
| Williams Eddie | A | 34804 | 12308 | 07 янв 2022 г. |
| Hunt Andrea | A | 28228 | 7521 | 07 янв 2022 г. |
Новостная лента
Why Is Catalyst Biosciences (CBIO) Stock Up 55% Today?
InvestorPlace
28 февр 2023 г. в 08:00
Catalyst Biosciences (NASDAQ: CBIO ) stock is rocketing higher on Tuesday after the company announced an asset purchase agreement with GC Biopharma. That agreement has Catalyst Biosciences selling three of its programs related to orphan hematology disorders to the company.
Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock
Seeking Alpha
15 авг 2022 г. в 12:23
Catalyst Biosciences is highly committed to its cash distribution plan to shareholders of up to $65 million in the near future, with only a $58 million market capitalization. If the proxy contest is cleared up between Catalyst and JDS1 and goes in favor of the executives of Catalyst, shareholders should expect an initial cash distribution of $45 million.